3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
12
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Blood Specimen Collection
123
Surveys and Questionnaires
82
Observation
49
Radiotherapy
40
Surgical Procedures, Operative
34
Drug Therapy
34
Biopsy
31
Specimen Handling
28
Data Collection
27
Watchful Waiting
20
Interviews as Topic
20
Magnetic Resonance Imaging
18
Immune Checkpoint Inhibitors
17
Liquid Biopsy
16
Magnetic Resonance Spectroscopy
15
Immunotherapy
15
Standard of Care
13
pembrolizumab
12
Tomography, X-Ray Computed
12
Ultrasonography
11
trastuzumab deruxtecan
10
lenvatinib
10
Radiosurgery
10
Nivolumab
10
Neoadjuvant Therapy
10
Carboplatin
10
Tissue Banks
9
Restraint, Physical
9
Radiation
9
Endoscopy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Observational
×
asciminib
×
Clear all
NCT05943522
2026-04-20
Asciminib RMP Study
Novartis
Recruiting
600 enrolled